Skip To Main Content
Emily N on Muck Rack

Emily N

As seen in: Nature, Frontiers
Covers:  Entertainment, Technology, Games, Music, Movie, Lifestyle, Fitness, Finance
Doesn't Cover: Medical

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Emily N’s Biography

Read Full Bio →

I have a passionate passion for creativity and innovation. Art and people are always the inspiration for me to work and grow. I always acquire and learn the new knowledge and experiences. I have experience in content management, article SEO and website.

Emily N’s Journalist Portfolio

Hộp Đen Cảm Xúc - Liêu Hà Trinh, Denis Đặng, Trung Quân - Livestream

Hộp Đen Cảm Xúc - Liêu Hà Trinh, Denis Đặng, Trung Quân - Livestream

Cùng đến lắng nghe những cảm xúc và những bí mật từ 2 vị khách mời Denis Đặng và Nguyễn Trần Trung Quân trong…

View article →
Humans of Vietnam - Bình đẳng

Humans of Vietnam - Bình đẳng

"Khi một bé trai từ 2-3 tuổi mà ôm gấu bông thay vì chơi chiếc xe thì nói lớn lên nó sẽ là Gay" 😔 😞 Bạn nghĩ…

View article →

Articles

Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma

|
By Emily N, Milica A. Margeta, Thomas Johnson, Youichi Shinozaki
| Frontiers
Introduction Glaucoma is a neurodegenerative disease characterized by retinal ganglion cell (RGC) death and optic nerve (ON) atrophy, causing progressive and permanent vision loss. As the leading cause of irreversible blindness worldwide, glaucoma is projected to affect 112 million people by 2040 (Tham et al., 2014). Currently, lowering intraocular pressure (IOP) is the only proven therapeutic option for glaucoma patients.
Open in Who Shared Issue with article?

Topical and Systemic GLP-1R Agonist Administration both Rescue Retinal Ganglion Cells in Hypertensive Glaucoma

|
By Emily N
| Frontiers
Emily C. Lawrence1, 2*, Michelle Guo1, Turner Schwartz2, Sergei Nikonov2, Jie Wu2, Jingwen Lu2, Jacob K. Sterling1, 2 and Qi N. Cui1, 2 1Scheie Eye Institute, Penn Presbyterian Medical Center, United States 2Perelman School of Medicine, University of Pennsylvania, United States The final, formatted version of the article will be published soon.
Open in Who Shared Issue with article?

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial - Nature Medicine

|
By Emily N, Carla G. S, Solange R. G, Rosa M. R
| Nature Verified
Abstract CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac.
Open in Who Shared Issue with article?
See all 3 articles